Justlina-M Tablet is a combination oral antihyperglycemic agent containing Metformin 500 mg and Linagliptin 2.5 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby aiding in glycemic control. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by preventing the degradation of incretin hormones, which increases insulin secretion and decreases glucagon release in a glucose-dependent manner. The synergistic effect of these two agents helps to achieve better glycemic control compared to monotherapy. Justlina-M is typically prescribed as an adjunct to diet and exercise to improve blood sugar levels in adults with type 2 diabetes when metformin alone is insufficient. It is important to monitor renal function prior to and during therapy, as metformin is contraindicated in patients with significant renal impairment. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while hypoglycemia risk is low but may increase when combined with other antidiabetic agents. Patients should adhere to prescribed dosing and report any unusual symptoms to their healthcare provider promptly.